Draft talk:Vidhya Rangaraju

Conflict of Interest Disclosure

I am the spouse of the subject of this article, Dr. Vidhya Rangaraju. I am submitting this draft via Articles for Creation for independent review to ensuring it meets notability guidelines (WP:PROF). I have restricted the content to factual statements supported by independent sources (NIH, Society for Neuroscience, The Scientist) and have avoided promotional language. Fabianb85 (talk) 17:34, 12 December 2025 (UTC)

Resubmission: Evidence of Academic Notability (WP:PROF)

Resubmitting with clarification on Academic Notability (WP:PROF). The subject qualifies under Criterion #1 (Significant Impact) and Criterion #2 (Major Awards).

Evidence for C1: Subject is the lead author of a highly cited paper in Cell (Rangaraju et al., 2014) with >860 citations (verified via Google Scholar), indicating significant impact in the field of neuroenergetics.

Evidence for C2: Subject is a winner of the NIH Director's New Innovator Award (DP2), a highly selective national honor for early-career scientists (part of the High-Risk, High-Reward program).

References have been updated to explicitly highlight citation metrics and award significance. Please review under WP:PROF guidelines rather than General Notability. Fabianb85 (talk) 21:14, 13 December 2025 (UTC)

Response to Reviewer Cabrils: Best Sources and Specific Criteria

Thanks for your thoughtful feedback. I've reviewed the guides you linked. I understand that you need to see the strongest evidence that separates her from a standard researcher.

Per your request, here are the WP:THREE best sources that establish independence and impact, followed by the specific WP:PROF criteria supported by her record of citations and awards.

1. The WP:THREE Best Sources

• 1. The Scientist Magazine (Independent Media ): https://www.the-scientist.com/how-mitochondria-stay-still-in-neurons-71720. This is a feature article ("How Mitochondria Stay Still in Neurons") in a major industry publication. It is intellectually independent of the subject and covers her specific findings on mitochondrial stabilization in depth.
• 2. Society for Neuroscience (Major Award Recognition): https://www.sfn.org/publications/latest-news/2024/09/16/society-for-neuroscience-2024-promotion-of-women-in-neuroscience-awards. This citation for the Janett Rosenberg Trubatch Career Development Award details her specific contributions to the field ("developed sophisticated ways to visualize ATP levels"). It confirms her recognition by the world's largest neuroscience organization.
• 3. Google Scholar (Impact Verification): https://scholar.google.com/citations?user=uudWngwAAAAJ&hl=en&oi=ao. This independent profile confirms a total citation count of >2,000. Crucially, it shows sustained high impact: she has five separate publications with over 100 citations each (883, 391, 268, 219, and 104 respectively), proving broad academic influence.

2. Specific Criteria Met (WP:NPROF)

Based on those sources and the other awards listed in the draft, she meets two specific academic criteria:

• Criterion #1 (Significant Impact): Met via the citation metrics (Source #3). With a primary research paper cited >880 times and four others cited >100 times, her work on local ATP synthesis is demonstrably foundational in the field of neuroenergetics.
• Criterion #2 (Major Awards): She meets this multiple times over. In addition to the NIH Director's New Innovator Award (https://commonfund.nih.gov/newinnovator/fundedresearch), the draft documents that she also won the Ben Barres Early Career Acceleration Award (from the Chan Zuckerberg Initiative)(https://chanzuckerberg.com/science/programs-resources/neurodegeneration-challenge/projects/) and the SfN Trubatch Award (Source #2). These are all highly selective prizes that clearly exceed "run of the mill" academic honors.

I hope this clarifies that her notability is based on a sustained record of high-impact awards and citations. Fabianb85 (talk) 04:08, 28 December 2025 (UTC)

Hi @Fabianb85,

Thank you for this information.

Firstly, I would encourage you to create a User Page as it will make communicating much more efficient (and you can then be notified when editors tag you in a post like this).

I note your declared conflict of interest as the subject's spouse- thank you for doing so. As I noted in my original comment, "In instances of a conflict of interest, the review of the page needs to be handled with care, mindful of the higher bar set by pages produced in circumstances of such a conflict."

I note that since the draft was first declined by @MCE89, your only substantive change to the draft was the addition of the following:

"This study has been cited over 870 times in peer-reviewed literature, establishing the link between local ATP synthesis and neurotransmission."

(This comment verges on WP:OR and I don't see it as a helpful addition to the draft.)

I then declined the draft and no substantive changes have been made since. I do note the helpful clarifications you have provided here on the draft's Talk page.

I agree that Rangaraju's work has been cited; and she has received a number of awards, including the Society of Neuroscience's Janett Rosenberg Trubatch Career Development Award that "promotes successful academic transitions prior to tenure by recognizing early career professionals" (my emphasis); and the NIH Director's New Innovator Award, again, emphasis on new.

However, taking into account the WP:COI, I do not feel that Rangaraju yet meets the standards set out in WP:NPROF, the gist of which is that the academic has reached an extremely high standard of recognition: for example C#3 "The person has been an elected member of a highly selective and prestigious scholarly society or association"; C#4 "The person's academic work has made a significant impact in the area of higher education, affecting a substantial number of academic institutions."; C#5 "The person has held a distinguished professor appointment at a major institution of higher education and research".

In my view it is WP:TOOSOON.

However, other reviewers may disagree and hence my efforts to go into some detail here to set out my reasoning.

Please feel free to respond here as I see the makings of a notable researcher in Rangaraju, and perhaps you can provide other compelling reasoning for why the draft, either as is, or following amendments made in the future (and I encourage you to do so) may meet the relevant criteria. Cabrils (talk) 07:39, 3 January 2026 (UTC)

[Posting this comment here as the draft's author posted it on the Draft page]

Hi @Cabrils:,

Thank you for the detailed comment of 3 January 2026 — both for the encouragement and for the specific feedback. I took your suggestion and created a user page at User:Fabianb85, where the COI disclosure is also recorded.

Per your guidance, I've substantively rewritten the draft rather than tweaking around the edges, and I've reorganized the notability case so that it rests squarely on WP:NPROF. You were right that the citation-count line I added between the first and second declines verged on WP:OR, and that the substantive evidence base hadn't really moved between submissions; that addition has been removed and replaced with third-party characterizations of the work.

The case I'm now making is on C1 and C2:

For C1 (significant research impact, demonstrated by independent reliable sources): Rangaraju has two first-author papers in Cell — on activity-driven local ATP synthesis (2014) and on spatially stable mitochondrial compartments fueling local translation (2019). The 2019 paper was the subject of a peer-reviewed Preview in Neuron by Rossoll and Bassell at the Mayo Clinic and Emory (doi:10.1016/j.neuron.2018.12.027), and has been engaged with substantively in body text by independent peer-reviewed reviews from groups at the University of Colorado (Rajgor et al., doi:10.3389/fcell.2021.711446), Albert Einstein College of Medicine (Kharod et al., doi:10.3389/fcell.2021.663367), the Achucarro Basque Center (Gamarra et al., doi:10.3389/fnint.2021.689208), Temple University (Gallo, doi:10.1002/dneu.22776), the University of Cologne (Thelen and Kye, doi:10.3389/fmolb.2019.00161), and the University of Bristol (Seager et al., doi:10.1042/ns20200008). Her senior-author work between 2024 and 2026 includes papers in Cell, Nature Communications (twice), Nature Metabolism, and Molecular Neurodegeneration. The 2024 VAP paper in Nature Communications was covered as a feature in The Scientist on 13 March 2024, with independent commentary from Thomas Schwarz (Boston Children's Hospital) and Xinnan Wang (Stanford). The Syn-ATP optical reporter she developed during her PhD is U.S. Patent 9,487,819 B2 and is distributed as Addgene plasmid 51819.

For C2 (major awards): the NIH Director's New Innovator Award (DP2, 2024), the Chan Zuckerberg Initiative Ben Barres Early Career Acceleration Award (2023), the Society for Neuroscience Janett Rosenberg Trubatch Career Development Award (2024), and the Society for Neuroscience Peter and Patricia Gruber International Research Award (2020). Earlier honors include the EMBO Long-Term Postdoctoral Fellowship (2015), the Marie Curie Actions Individual Fellowship (2016–2017), and the Lindau Nobel Laureate Meeting Award (2018).

I'm not claiming C3, C4, or C5 — your earlier points on those were correct, and the rewrite drops anything that hinted otherwise. WP:NPROF is "an alternative to" WP:GNG, so meeting one is sufficient; I'm relying on C1 + C2.

The body of the article has also been rewritten so that it's verifiable from independent sources rather than from MPFI or other affiliated material — I'm happy to discuss any specific source if it would help. Thank you again for the careful review and for leaving the door open. Fabianb85 (talk) 21:28, 29 April 2026 (UTC)

Hi Fabianb85, thanks for the update. Well done re-drafting the draft, there's a lot of work in that.

Notwithstanding your good amendments, and clearly presented reasoning, I am still on the fence on this. Part of me is feeling it could be WP:TOOSOON; and another part remains concerned that the draft has been produced wiht a conflict of interest. As I noted in my original comment, "Given the conflict, the review of the page needs to be handled with care, mindful of the higher bar set by pages produced in circumstances of conflict of interest. Such pages typically may read too much like a promotional CV or advertorial (see WP:PROMO), which Wikipedia is not; and/or contain prose that is not of a standard appropriate for an encyclopaedia (also see WP:PEACOCK and WP:NPV)."

Other reviewers may feel differently however, so I shall leave it others to make the call on this. I do wish you all the best. Cabrils (talk) 05:11, 30 April 2026 (UTC)

Hi @Cabrils:,

Thank you for taking the time to revisit this and for the kind words on the redraft. I take the WP:PROMO and WP:PEACOCK point seriously; I'll do another careful pass with that specific lens. I appreciate you stepping back and leaving it to other reviewers, and I appreciate the considered, patient way you've engaged with this from the start. Best regards. Fabianb85 (talk) 06:09, 30 April 2026 (UTC)

@Fabianb85 Thanks for the kind words. I will keep thinking about this, it is by and large a well presented draft. Cabrils (talk) 22:31, 30 April 2026 (UTC)

Resubmission rationale (April 2026)

Posting the substantive resubmission rationale here on the talk page, where the conversation has been taking place. The draft was substantively rewritten following the reviewer comment of 3 January 2026 and resubmitted on 29 April 2026; the WP:PROMO/PEACOCK concern raised in the 30 April 2026 follow-up has since been addressed via a tone pass on the article body.

The notability case rests on WP:NPROF.

C1 — significant research impact, demonstrated by independent reliable sources. First-author papers in Cell on activity-driven local ATP synthesis (2014) and on spatially stable mitochondrial compartments fueling local translation (2019). The 2019 paper is the subject of a peer-reviewed Preview in Neuron by Rossoll and Bassell (Mayo Clinic and Emory; doi:10.1016/j.neuron.2018.12.027). Independent peer-reviewed reviews engaging substantively with the work include Rajgor, Welle and Smith (University of Colorado, doi:10.3389/fcell.2021.711446); Kharod, Hwang and Das (Albert Einstein College of Medicine, doi:10.3389/fcell.2021.663367); Gamarra et al. (Achucarro Basque Center, doi:10.3389/fnint.2021.689208); Gallo (Temple University, doi:10.1002/dneu.22776); Thelen and Kye (University of Cologne, doi:10.3389/fmolb.2019.00161); and Seager, Lee and Henley (University of Bristol, doi:10.1042/ns20200008). Senior-author papers in 2024–2026 appear in Cell, Nature Communications (twice), Nature Metabolism, and Molecular Neurodegeneration. The 2024 VAP paper (Nature Communications 15:205) is the subject of an independent feature in The Scientist (13 March 2024) with commentary from Thomas Schwarz (Boston Children's Hospital) and Xinnan Wang (Stanford University). The Syn-ATP optical reporter is U.S. Patent 9,487,819 B2, distributed as Addgene plasmid 51819.

C2 — major awards. NIH Director's New Innovator Award (DP2, 2024); Chan Zuckerberg Initiative Ben Barres Early Career Acceleration Award (2023); Society for Neuroscience Janett Rosenberg Trubatch Career Development Award (2024); Society for Neuroscience Peter and Patricia Gruber International Research Award (2020); EMBO Long-Term Postdoctoral Fellowship (2015); Marie Curie Actions Individual Fellowship (2016–2017); Lindau Nobel Laureate Meeting Award (2018).

WP:NPROF is "an alternative to" WP:GNG, so meeting one is sufficient. C3, C4, and C5 are not claimed; the earlier reviewer comment correctly noted those.

The COI disclosure remains on this talk page and on User:Fabianb85. The body of the article has been written so it is verifiable from the cited independent sources rather than from MPFI or other affiliated material. Fabianb85 (talk) 06:58, 30 April 2026 (UTC)